_id
695fb671c2e91020a7bd420d
Ticker
0HF9.LSE
Name
Amicus Therapeutics, Inc.
Exchange
LSE
Address
47 Hulfish Street, Princeton, NJ, United States, 08542
Country
UK
Sector
Industry
Currency
USD
Website
https://amicusrx.com
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Last Close
14.3
Volume
2500
Current Price
14.2907
Last Updated
2026-01-08T13:51:44.870Z
Ipo Date
-
Market Cap
417715968000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
169061000
Cost Of Revenue
21341000
Gross Profit
147720000
Operating Expenses
113451000
Operating Income
34269000
Interest Expense
11711000
Pretax Income
34274000
Net Income
17306000
Eps
0.0557478504558532
Dividends Per Share
-
Shares Outstanding
189290000
Income Tax Expense
16968000
EBITDA
47859000
Operating Margin
20.270198330780016
Total Other Income Expense Net
5000
Cash
190553000
Short Term Investments
73290000
Receivables
113838000
Inventories
177928000
Total Current Assets
594066000
Property Plant Equipment
49308000
Total Assets
868811000
Payables
19103000
Short Term Debt
8662000
Long Term Debt
-
Total Liabilities
638387000
Equity
230424000
Bs_currency_symbol
-
Depreciation
1874000
Change In Working Capital
-9885000
Cash From Operations
35660000
Capital Expenditures
382000
Cash From Investing
-1299000
Cash From Financing
-1319000
Net Change In Cash
31851000
Cf_currency_symbol
-
PE
-
PB
19.25282059466809
ROE
7.51050237822449
ROA
1.9919176898082553
FCF
35278000
Fcf Percent
0.20867024328496814
Piotroski FScore
4
Health Score
55
Deep Value Investing Score
6
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
3
Growth Investing Score
3
Momentum Investing Score
3
Net Net Investing Score
4
Quality Investing Score
5
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
169061000
Quarters > 0 > income Statement > cost Of Revenue
21341000
Quarters > 0 > income Statement > gross Profit
147720000
Quarters > 0 > income Statement > operating Expenses
113451000
Quarters > 0 > income Statement > operating Income
34269000
Quarters > 0 > income Statement > interest Expense
11711000
Quarters > 0 > income Statement > pretax Income
34274000
Quarters > 0 > income Statement > net Income
17306000
Quarters > 0 > income Statement > eps
0.0557478504558532
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
310433494
Quarters > 0 > income Statement > income Tax Expense
16968000
Quarters > 0 > income Statement > EBITDA
47859000
Quarters > 0 > income Statement > operating Margin
20.270198330780016
Quarters > 0 > income Statement > total Other Income Expense Net
5000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
190553000
Quarters > 0 > balance Sheet > short Term Investments
73290000
Quarters > 0 > balance Sheet > receivables
113838000
Quarters > 0 > balance Sheet > inventories
177928000
Quarters > 0 > balance Sheet > total Current Assets
594066000
Quarters > 0 > balance Sheet > property Plant Equipment
49308000
Quarters > 0 > balance Sheet > total Assets
868811000
Quarters > 0 > balance Sheet > payables
19103000
Quarters > 0 > balance Sheet > short Term Debt
8662000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
638387000
Quarters > 0 > balance Sheet > equity
230424000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
17306000
Quarters > 0 > cash Flow > depreciation
1874000
Quarters > 0 > cash Flow > change In Working Capital
-9885000
Quarters > 0 > cash Flow > cash From Operations
35660000
Quarters > 0 > cash Flow > capital Expenditures
382000
Quarters > 0 > cash Flow > cash From Investing
-1299000
Quarters > 0 > cash Flow > cash From Financing
-1319000
Quarters > 0 > cash Flow > net Change In Cash
31851000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
0.0557478504558532
Quarters > 0 > ratios > PB
19.25282059466809
Quarters > 0 > ratios > ROE
7.51050237822449
Quarters > 0 > ratios > ROA
1.9919176898082553
Quarters > 0 > ratios > FCF
35278000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.20867024328496814
Quarters > 0 > health Score
55
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
154688000
Quarters > 1 > income Statement > cost Of Revenue
15217000
Quarters > 1 > income Statement > gross Profit
139471000
Quarters > 1 > income Statement > operating Expenses
148945000
Quarters > 1 > income Statement > operating Income
-9474000
Quarters > 1 > income Statement > interest Expense
11565000
Quarters > 1 > income Statement > pretax Income
-19181000
Quarters > 1 > income Statement > net Income
-24420000
Quarters > 1 > income Statement > eps
-0.07922031739928354
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
308254256
Quarters > 1 > income Statement > income Tax Expense
5239000
Quarters > 1 > income Statement > EBITDA
-5764000
Quarters > 1 > income Statement > operating Margin
-6.124586263963591
Quarters > 1 > income Statement > total Other Income Expense Net
-9707000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
158702000
Quarters > 1 > balance Sheet > short Term Investments
72296000
Quarters > 1 > balance Sheet > receivables
105849000
Quarters > 1 > balance Sheet > inventories
154875000
Quarters > 1 > balance Sheet > total Current Assets
538007000
Quarters > 1 > balance Sheet > property Plant Equipment
50558000
Quarters > 1 > balance Sheet > total Assets
815303000
Quarters > 1 > balance Sheet > payables
13893000
Quarters > 1 > balance Sheet > short Term Debt
8610000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
610999000
Quarters > 1 > balance Sheet > equity
204304000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-24420000
Quarters > 1 > cash Flow > depreciation
1852000
Quarters > 1 > cash Flow > change In Working Capital
-29052000
Quarters > 1 > cash Flow > cash From Operations
-26526000
Quarters > 1 > cash Flow > capital Expenditures
2403000
Quarters > 1 > cash Flow > cash From Investing
-5778000
Quarters > 1 > cash Flow > cash From Financing
-400000
Quarters > 1 > cash Flow > net Change In Cash
-22717000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.07922031739928354
Quarters > 1 > ratios > PB
21.561834796280053
Quarters > 1 > ratios > ROE
-11.95277625499256
Quarters > 1 > ratios > ROA
-2.9952054634902607
Quarters > 1 > ratios > FCF
-28929000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-0.18701515308233346
Quarters > 1 > health Score
12
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
125249000
Quarters > 2 > income Statement > cost Of Revenue
11698000
Quarters > 2 > income Statement > gross Profit
113551000
Quarters > 2 > income Statement > operating Expenses
121503000
Quarters > 2 > income Statement > operating Income
-7952000
Quarters > 2 > income Statement > interest Expense
11455000
Quarters > 2 > income Statement > pretax Income
-18045000
Quarters > 2 > income Statement > net Income
-21686000
Quarters > 2 > income Statement > eps
-0.0704802102466987
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
307689207
Quarters > 2 > income Statement > income Tax Expense
3641000
Quarters > 2 > income Statement > EBITDA
-4753000
Quarters > 2 > income Statement > operating Margin
-6.348952885851385
Quarters > 2 > income Statement > total Other Income Expense Net
-10093000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
181657000
Quarters > 2 > balance Sheet > short Term Investments
68916000
Quarters > 2 > balance Sheet > receivables
88323000
Quarters > 2 > balance Sheet > inventories
132412000
Quarters > 2 > balance Sheet > total Current Assets
510799000
Quarters > 2 > balance Sheet > property Plant Equipment
50856000
Quarters > 2 > balance Sheet > total Assets
789839000
Quarters > 2 > balance Sheet > payables
14451000
Quarters > 2 > balance Sheet > short Term Debt
8562000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
596281000
Quarters > 2 > balance Sheet > equity
193558000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-21686000
Quarters > 2 > cash Flow > depreciation
1837000
Quarters > 2 > cash Flow > change In Working Capital
6010000
Quarters > 2 > cash Flow > cash From Operations
7758000
Quarters > 2 > cash Flow > capital Expenditures
212000
Quarters > 2 > cash Flow > cash From Investing
-32861000
Quarters > 2 > cash Flow > cash From Financing
-11700000
Quarters > 2 > cash Flow > net Change In Cash
-31984000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.0704802102466987
Quarters > 2 > ratios > PB
22.7171914902763
Quarters > 2 > ratios > ROE
-11.203876874115252
Quarters > 2 > ratios > ROA
-2.745622842123521
Quarters > 2 > ratios > FCF
7546000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
0.06024798601186437
Quarters > 2 > health Score
14
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
149706000
Quarters > 3 > income Statement > cost Of Revenue
14836000
Quarters > 3 > income Statement > gross Profit
134870000
Quarters > 3 > income Statement > operating Expenses
118899000
Quarters > 3 > income Statement > operating Income
15971000
Quarters > 3 > income Statement > interest Expense
11958000
Quarters > 3 > income Statement > pretax Income
7934000
Quarters > 3 > income Statement > net Income
14739000
Quarters > 3 > income Statement > eps
0.04928744826059398
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
299041653
Quarters > 3 > income Statement > income Tax Expense
-6805000
Quarters > 3 > income Statement > EBITDA
21933000
Quarters > 3 > income Statement > operating Margin
10.66824308978932
Quarters > 3 > income Statement > total Other Income Expense Net
-8037000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
213752000
Quarters > 3 > balance Sheet > short Term Investments
36194000
Quarters > 3 > balance Sheet > receivables
101099000
Quarters > 3 > balance Sheet > inventories
118782000
Quarters > 3 > balance Sheet > total Current Assets
504736000
Quarters > 3 > balance Sheet > property Plant Equipment
51661000
Quarters > 3 > balance Sheet > total Assets
785033000
Quarters > 3 > balance Sheet > payables
12947000
Quarters > 3 > balance Sheet > short Term Debt
8455000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
590988000
Quarters > 3 > balance Sheet > equity
194045000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
14739000
Quarters > 3 > cash Flow > depreciation
2041000
Quarters > 3 > cash Flow > change In Working Capital
-43739000
Quarters > 3 > cash Flow > cash From Operations
-3916000
Quarters > 3 > cash Flow > capital Expenditures
288000
Quarters > 3 > cash Flow > cash From Investing
-20392000
Quarters > 3 > cash Flow > cash From Financing
1097000
Quarters > 3 > cash Flow > net Change In Cash
-20104000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
0.04928744826059398
Quarters > 3 > ratios > PB
22.023317016811045
Quarters > 3 > ratios > ROE
7.595660800329821
Quarters > 3 > ratios > ROA
1.8775006910537517
Quarters > 3 > ratios > FCF
-4204000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.02808170681201822
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
528295000
Annuals > 0 > income Statement > cost Of Revenue
52943000
Annuals > 0 > income Statement > gross Profit
475352000
Annuals > 0 > income Statement > operating Expenses
450476000
Annuals > 0 > income Statement > operating Income
24876000
Annuals > 0 > income Statement > interest Expense
49598000
Annuals > 0 > income Statement > pretax Income
-28756000
Annuals > 0 > income Statement > net Income
-56106000
Annuals > 0 > income Statement > eps
-0.18432849552235775
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
304380502
Annuals > 0 > income Statement > income Tax Expense
27350000
Annuals > 0 > income Statement > EBITDA
29389000
Annuals > 0 > income Statement > operating Margin
4.708732810266991
Annuals > 0 > income Statement > total Other Income Expense Net
-53632000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
213752000
Annuals > 0 > balance Sheet > short Term Investments
36194000
Annuals > 0 > balance Sheet > receivables
101099000
Annuals > 0 > balance Sheet > inventories
118782000
Annuals > 0 > balance Sheet > total Current Assets
504736000
Annuals > 0 > balance Sheet > property Plant Equipment
51661000
Annuals > 0 > balance Sheet > total Assets
785033000
Annuals > 0 > balance Sheet > payables
12947000
Annuals > 0 > balance Sheet > short Term Debt
8455000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
590988000
Annuals > 0 > balance Sheet > equity
194045000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-56106000
Annuals > 0 > cash Flow > depreciation
8547000
Annuals > 0 > cash Flow > change In Working Capital
-98943000
Annuals > 0 > cash Flow > cash From Operations
-33891000
Annuals > 0 > cash Flow > capital Expenditures
3553000
Annuals > 0 > cash Flow > cash From Investing
-560000
Annuals > 0 > cash Flow > cash From Financing
5121000
Annuals > 0 > cash Flow > net Change In Cash
-33361000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-0.18432849552235775
Annuals > 0 > ratios > PB
22.416503594173516
Annuals > 0 > ratios > ROE
-28.913911721507894
Annuals > 0 > ratios > ROA
-7.146960701015116
Annuals > 0 > ratios > FCF
-37444000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.07087706679033494
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
399356000
Annuals > 1 > income Statement > cost Of Revenue
37326000
Annuals > 1 > income Statement > gross Profit
362030000
Annuals > 1 > income Statement > operating Expenses
439241000
Annuals > 1 > income Statement > operating Income
-77211000
Annuals > 1 > income Statement > interest Expense
50149000
Annuals > 1 > income Statement > pretax Income
-150101000
Annuals > 1 > income Statement > net Income
-151584000
Annuals > 1 > income Statement > eps
-0.5135576680008436
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
295164515
Annuals > 1 > income Statement > income Tax Expense
1483000
Annuals > 1 > income Statement > EBITDA
-92079000
Annuals > 1 > income Statement > operating Margin
-19.33387754284398
Annuals > 1 > income Statement > total Other Income Expense Net
-72890000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
246994000
Annuals > 1 > balance Sheet > short Term Investments
39206000
Annuals > 1 > balance Sheet > receivables
87632000
Annuals > 1 > balance Sheet > inventories
59696000
Annuals > 1 > balance Sheet > total Current Assets
483061000
Annuals > 1 > balance Sheet > property Plant Equipment
57979000
Annuals > 1 > balance Sheet > total Assets
777880000
Annuals > 1 > balance Sheet > payables
15120000
Annuals > 1 > balance Sheet > short Term Debt
8324000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
617706000
Annuals > 1 > balance Sheet > equity
160174000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-151584000
Annuals > 1 > cash Flow > depreciation
7873000
Annuals > 1 > cash Flow > change In Working Capital
-47990000
Annuals > 1 > cash Flow > cash From Operations
-69091000
Annuals > 1 > cash Flow > capital Expenditures
7440000
Annuals > 1 > cash Flow > cash From Investing
98064000
Annuals > 1 > cash Flow > cash From Financing
61677000
Annuals > 1 > cash Flow > net Change In Cash
96962000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.5135576680008436
Annuals > 1 > ratios > PB
26.33453328574238
Annuals > 1 > ratios > ROE
-94.6370821731367
Annuals > 1 > ratios > ROA
-19.48681030493135
Annuals > 1 > ratios > FCF
-76531000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-0.19163603401476376
Annuals > 1 > health Score
9
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
329233000
Annuals > 2 > income Statement > cost Of Revenue
38599000
Annuals > 2 > income Statement > gross Profit
290634000
Annuals > 2 > income Statement > operating Expenses
502754000
Annuals > 2 > income Statement > operating Income
-212120000
Annuals > 2 > income Statement > interest Expense
37119000
Annuals > 2 > income Statement > pretax Income
-242039000
Annuals > 2 > income Statement > net Income
-236568000
Annuals > 2 > income Statement > eps
-0.8184124167701923
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
289057198
Annuals > 2 > income Statement > income Tax Expense
-5471000
Annuals > 2 > income Statement > EBITDA
-199578000
Annuals > 2 > income Statement > operating Margin
-64.4285354141292
Annuals > 2 > income Statement > total Other Income Expense Net
-29919000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
148813000
Annuals > 2 > balance Sheet > short Term Investments
144782000
Annuals > 2 > balance Sheet > receivables
66196000
Annuals > 2 > balance Sheet > inventories
23816000
Annuals > 2 > balance Sheet > total Current Assets
423816000
Annuals > 2 > balance Sheet > property Plant Equipment
60312000
Annuals > 2 > balance Sheet > total Assets
724167000
Annuals > 2 > balance Sheet > payables
15413000
Annuals > 2 > balance Sheet > short Term Debt
8552000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
601120000
Annuals > 2 > balance Sheet > equity
123047000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-236568000
Annuals > 2 > cash Flow > depreciation
5342000
Annuals > 2 > cash Flow > change In Working Capital
-39880000
Annuals > 2 > cash Flow > cash From Operations
-166575000
Annuals > 2 > cash Flow > capital Expenditures
3766000
Annuals > 2 > cash Flow > cash From Investing
92316000
Annuals > 2 > cash Flow > cash From Financing
-7463000
Annuals > 2 > cash Flow > net Change In Cash
-96341000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.8184124167701923
Annuals > 2 > ratios > PB
33.571153294745905
Annuals > 2 > ratios > ROE
-192.25824278527716
Annuals > 2 > ratios > ROA
-32.66760291479728
Annuals > 2 > ratios > FCF
-170341000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.5173873821882983
Annuals > 2 > health Score
8
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
305514000
Annuals > 3 > income Statement > cost Of Revenue
34466000
Annuals > 3 > income Statement > gross Profit
271048000
Annuals > 3 > income Statement > operating Expenses
477482000
Annuals > 3 > income Statement > operating Income
-206434000
Annuals > 3 > income Statement > interest Expense
32471000
Annuals > 3 > income Statement > pretax Income
-241554000
Annuals > 3 > income Statement > net Income
-250460000
Annuals > 3 > income Statement > eps
-0.9227697567580248
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
271421986
Annuals > 3 > income Statement > income Tax Expense
8906000
Annuals > 3 > income Statement > EBITDA
-202874000
Annuals > 3 > income Statement > operating Margin
-67.56940762125467
Annuals > 3 > income Statement > total Other Income Expense Net
-35120000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
245197000
Annuals > 3 > balance Sheet > short Term Investments
237299000
Annuals > 3 > balance Sheet > receivables
52672000
Annuals > 3 > balance Sheet > inventories
26818000
Annuals > 3 > balance Sheet > total Current Assets
596834000
Annuals > 3 > balance Sheet > property Plant Equipment
63082000
Annuals > 3 > balance Sheet > total Assets
905140000
Annuals > 3 > balance Sheet > payables
21513000
Annuals > 3 > balance Sheet > short Term Debt
7409000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
597771000
Annuals > 3 > balance Sheet > equity
307369000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-250460000
Annuals > 3 > cash Flow > depreciation
6209000
Annuals > 3 > cash Flow > change In Working Capital
-18585000
Annuals > 3 > cash Flow > cash From Operations
-202491000
Annuals > 3 > cash Flow > capital Expenditures
3884000
Annuals > 3 > cash Flow > cash From Investing
78761000
Annuals > 3 > cash Flow > cash From Financing
212073000
Annuals > 3 > cash Flow > net Change In Cash
83294000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.9227697567580248
Annuals > 3 > ratios > PB
12.619392896909577
Annuals > 3 > ratios > ROE
-81.48512049035524
Annuals > 3 > ratios > ROA
-27.670857546898826
Annuals > 3 > ratios > FCF
-206375000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.6755009590395202
Annuals > 3 > health Score
16
Valuation > metrics > PE
0.0557478504558532
Valuation > metrics > PB
19.25282059466809
Valuation > final Score
40
Valuation > verdict
221.2% Overvalued
Profitability > metrics > ROE
7.51050237822449
Profitability > metrics > ROA
2.9131443307645952
Profitability > metrics > Net Margin
0.102365418399276
Profitability > final Score
39
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.770488317189182
Risk > metrics > Interest Coverage
2.9262232089488514
Risk > final Score
30
Risk > verdict
High
Liquidity > metrics > Current Ratio
21.396218260399785
Liquidity > metrics > Quick Ratio
14.987862416711687
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
40
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
39
Prev Risks > 0
15
Prev Risks > 1
3
Prev Risks > 2
11
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:28.972Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-18
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
0.16
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Amicus Therapeutics, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
0.16
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.